SEC Comment Letter 0000000000-23-005428 to NOVARTIS AG (NVS)

NOVARTIS AG
Date: May 22, 2023 · CIK: 0001114448 · Accession: 0000000000-23-005428

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-15024

Date

May 22, 2023

Author

Not clearly detected

Form

UPLOAD

Company

NOVARTIS AG

Letter

United States securities and exchange commission logo May 22, 2023 Harry Kirsch Chief Financial Officer Novartis AG Lichtstrasse 35 4056 Basel, Switzerland Re:Novartis AG Form 20-F for the Fiscal Year Ended December 31, 2022 Filed February 1, 2023 File No. 001-15024 Dear Harry Kirsch: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Karen L. Hale

Show Raw Text

United States securities and exchange commission logo
May 22, 2023
Harry Kirsch
Chief Financial Officer
Novartis AG
Lichtstrasse 35
4056 Basel, Switzerland
Re:Novartis AG
Form 20-F for the Fiscal Year Ended December 31, 2022
Filed February 1, 2023
File No. 001-15024
Dear Harry Kirsch:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Karen L. Hale

SecProbe.io